EFM
LYEL icon

E Fund Management’s Lyell Immunopharma LYEL Stock Holding History

E Fund Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,091
Closed -$32K – 318
2023
Q3 		$32K Buy
1,091
+216
+25% +$10.3K ﹤0.01% 292
2023
Q2 		$56K Sell
875
-562
-39% -$31.1K ﹤0.01% 308
2023
Q1 		$68K Sell
1,437
-72
-5% -$3.85K 0.01% 329
2022
Q4 		$105K Buy
1,509
+799
+113% +$79.4K 0.01% 328
2022
Q3 		$104K Buy
+710
New +$96.1K 0.01% 326

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
WA
WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

E Fund Management's LYEL Position: Q4 2023 in Review

E Fund Management sold out of Lyell Immunopharma (LYEL) in Q4 2023, closing a stake of 1,091 shares — an estimated $32K sold.

E Fund Management first reported a position in LYEL in Q3 2022 and held it in 5 quarters. The position peaked at $105K in Q4 2022. 118 funds tracked by Wall St. Rank hold LYEL as of Q4 2023.

  • E Fund Management reported no remaining Lyell Immunopharma position as of Q4 2023 after selling out during the quarter.
  • E Fund Management sold 1,091 Lyell Immunopharma shares in Q4 2023, an estimated $32K.
  • E Fund Management first reported a position in Lyell Immunopharma in Q3 2022 and held it in 5 quarters.
  • E Fund Management's Lyell Immunopharma position peaked at $105K in Q4 2022.
  • 118 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2023.

Based on E Fund Management's 13F filing for Q4 2023, filed 7 Feb 2024.